Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence.

Published on Dec 14, 2017in The Journal of Nuclear Medicine7.887
· DOI :10.2967/JNUMED.117.202945
Jeremie Calais20
Estimated H-index: 20
(UCLA Medical Center),
Wolfgang P. Fendler30
Estimated H-index: 30
(UCLA Medical Center)
+ 14 AuthorsKen Herrmann2
Estimated H-index: 2
(UCLA Medical Center)
Sources
Abstract
In this prospective survey of referring physicians, we investigated whether and how 68Ga-labeled prostate-specific membrane antigen 11 (68Ga-PSMA-11) PET/CT affects the implemented management of prostate cancer patients with biochemical recurrence (BCR). Methods: We conducted a prospective survey of physicians ({"type":"clinical-trial","attrs":{"text":"NCT02940262","term_id":"NCT02940262"}}NCT02940262) who referred 161 patients with prostate cancer BCR (median prostate-specific antigen value, 1.7 ng/mL; range, 0.05–202 ng/mL). Referring physicians completed one questionnaire before the scan to indicate the treatment plan without 68Ga-PSMA-11 PET/CT information (Q1; n = 101), one immediately after the scan to denote intended management changes (Q2; n = 101), and one 3–6 mo later to document the final implemented management (Q3; n = 56). The implemented management was also obtained via electronic chart review or patient contact (n = 45). Results: A complete documented management strategy (Q1 + Q2 + implemented management) was available for 101 of 161 patients (63%). Seventy-six of these (75%) had a positive 68Ga-PSMA-11 PET/CT result. The implemented management differed from the prescan intended management (Q1) in 54 of 101 patients (53%). The postscan intended management (Q2) differed from the prescan intended management (Q1) in 62 of 101 patients (61%); however, these intended changes were not implemented in 29 of 62 patients (47%). Pelvic nodal and extrapelvic metastatic disease on 68Ga-PSMA-11 PET/CT (PSMA T0N1M0 and PSMA T0N1M1 patterns) was significantly associated with implemented management changes (P = 0.001 and 0.05). Conclusion: Information from 68Ga-PSMA-11 PET/CT brings about management changes in more than 50% of prostate cancer patients with BCR (54/101; 53%). However, intended management changes early after 68Ga-PSMA-11 PET/CT frequently differ from implemented management changes.
Figures & Tables
Download
📖 Papers frequently viewed together
532 Citations
65 Citations
646 Citations
References25
Newest
Purpose The purpose of our study was to assess 18F–DCFBC PET/CT, a PSMA targeted PET agent, for lesion detection and clinical management of biochemical relapse in prostate cancer patients after primary treatment.
32 CitationsSource
#1Paul Roach (RNSH: Royal North Shore Hospital)H-Index: 22
#2Roslyn J. FrancisH-Index: 22
Last. Andrew M. Scott (Austin Hospital)H-Index: 87
view all 15 authors...
: 68Ga-PSMA PET/CT scanning has been shown to be more sensitive than conventional imaging techniques in patients with prostate cancer. This prospective Australian multicenter study assessed whether 68Ga-PSMA PET/CT imaging affects management intent in patients with primary or recurrent prostate cancer. Methods: Before undertaking 68Ga-PSMA PET imaging, referring medical specialists completed a questionnaire detailing relevant demographic and clinical data as well as their proposed management pla...
146 CitationsSource
#1Asim Afaq (UCLH: University College Hospital)H-Index: 4
#1Asim Afaq (UCLH: University College Hospital)H-Index: 14
Last. Jamshed Bomanji (UCL: University College London)H-Index: 52
view all 10 authors...
: The objective of this study was to assess the impact of 68Ga-prostate-specific membrane antigen (68Ga-PSMA) PET/CT on the management of prostate cancer in patients with biochemical recurrence (BCR). Methods: Documented management plans before and after 68Ga-PSMA PET/CT in 100 patients with BCR were retrospectively reviewed, and changes in plans were recorded. Results: Management changed after 68Ga-PSMA PET/CT in 39 patients (39%). The management changes occurred in 23 (33.8%) of 68 patients wi...
39 CitationsSource
#1Simone Albisinni (ULB: Université libre de Bruxelles)H-Index: 14
#2Carlos Artigas (ULB: Université libre de Bruxelles)H-Index: 7
Last. Roland van Velthoven (ULB: Université libre de Bruxelles)H-Index: 23
view all 14 authors...
Objective To assess the impact of a novel molecular imaging technique, 68Ga-(HBED-CC)-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT), in the clinical management of patients with prostate cancer with rising prostate-specific antigen (PSA) after treatment with curative intent. Patients and Methods In all, 131 consecutive patients were referred to our centre for a 68Ga-PSMA PET/CT in the setting of recurring prostate cancer. Of these patients, 11...
71 CitationsSource
#1Sarah Schwarzenboeck (University of Rostock)H-Index: 6
#2Isabel Rauscher (TUM: Technische Universität München)H-Index: 20
Last. Matthias Eiber (TUM: Technische Universität München)H-Index: 22
view all 9 authors...
Targeting the prostate-specific membrane antigen (PSMA) with Ga-68-labeled and F-18-labeled PET agents has become increasingly important in recent years. Imaging of biochemically recurrent prostate cancer has been established as a widely accepted clinical indication for PSMA ligand PET/CT in many parts of the world because of the results of multiple, primarily retrospective, studies that indicate superior detection efficacy compared with standard-of-care imaging. For high-risk primary prostate c...
76 CitationsSource
#1Thomas A. Hope (UCSF: University of California, San Francisco)H-Index: 39
#2Rahul Aggarwal (UCSF: University of California, San Francisco)H-Index: 26
Last. Peter R. Carroll (UCSF: University of California, San Francisco)H-Index: 141
view all 11 authors...
: The purpose of this prospective study was to estimate the effect of 68Ga-labeled prostate-specific membrane antigen (PSMA)-11 PET on the intended management of patients with biochemically recurrent prostate cancer. Methods: Pre- and postimaging surveys were filled out by the referring providers for patients with biochemical recurrence who were imaged using 68Ga-PSMA-11 PET. The inclusion criterion for this study was a prostate-specific antigen (PSA) doubling time of less than 12 mo after initi...
65 CitationsSource
#1Ali Afshar-Oromieh (University Hospital Heidelberg)H-Index: 37
#2Tim Holland-Letz (DKFZ: German Cancer Research Center)H-Index: 27
Last. Uwe Haberkorn (University Hospital Heidelberg)H-Index: 85
view all 16 authors...
Purpose Since the clinical introduction of 68Ga-PSMA-11 PET/CT, this imaging method has rapidly spread and is now regarded as a significant step forward in the diagnosis of recurrent prostate cancer (PCa). The aim of this study was to analyse the influence of several variables with possible influence on PSMA ligand uptake in a large cohort.
264 CitationsSource
#1Jeremie Calais (UCLA: University of California, Los Angeles)H-Index: 20
#2Johannes Czernin (UCLA: University of California, Los Angeles)H-Index: 94
Last. Ken Herrmann (University of Duisburg-Essen)H-Index: 67
view all 16 authors...
In this prospective referring-physician-based survey, we investigated the definite clinical impact of Ga-DOTATATE PET/CT on managing patients with neuroendocrine tumors (NETs). We prospectively studied 130 patients with Ga-DOTATATE PET/CT referred for initial or subsequent management decisions (NCT02174679). Referring physicians completed one questionnaire before the scan (Q1) to indicate the treatment plan without PET/CT information, one immediately after review of the imaging report to denote ...
15 CitationsSource
#1Wolfgang P. Fendler (LMU: Ludwig Maximilian University of Munich)H-Index: 30
#2Jeremie Calais (UCLA: University of California, Los Angeles)H-Index: 20
Last. Matthias Eiber (UCLA: University of California, Los Angeles)H-Index: 22
view all 23 authors...
Background: The interobserver agreement for (68)Ga-PSMA-11 Positron Emission Tomography/Computed Tomography (PET/CT) study interpretations in patients with prostate cancer is unknown. Methods:(68)Ga-PSMA-11 PET/CT was performed in 50 patients with prostate cancer for biochemical recurrence (n = 25), primary diagnosis (n = 10), biochemical persistence after primary therapy (n = 5) or staging of known metastatic disease (n = 10). Images were reviewed by 16 observers who used a standardized approac...
67 CitationsSource
#1Wolfgang P. Fendler (LMU: Ludwig Maximilian University of Munich)H-Index: 30
#2Matthias Eiber (TUM: Technische Universität München)H-Index: 22
Last. Ken Herrmann (UCLA: University of California, Los Angeles)H-Index: 67
view all 18 authors...
The aim of this guideline is to provide standards for the recommendation, performance, interpretation and reporting of 68Ga-PSMA PET/CT for prostate cancer imaging. These recommendations will help to improve accuracy, precision, and repeatability of 68Ga-PSMA PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice.
242 CitationsSource
Cited By59
Newest
#1Amy DaviesH-Index: 1
Last. Eva Segelov (Monash University)H-Index: 24
view all 0 authors...
OBJECTIVE PSMA PET/CT has demonstrated superior sensitivity over conventional imaging in the detection of local and distant recurrence in biochemically relapsed (BCR) prostate cancer. We prospectively investigated the management impact of 68 Ga-PSMA PET/CT imaging in men with BCR, with the aim of identifying baseline clinicopathological predictors for management change. PATIENTS AND METHODS Men with BCR who met eligibility criteria underwent 68 Ga-PSMA-11 PET/CT at Monash Health (Melbourne, Aust...
Source
#1Chentao Jin (ZJU: Zhejiang University)H-Index: 4
#2Xiaoyun Luo (ZJU: Zhejiang University)
Last. Mei Tian (ZJU: Zhejiang University)H-Index: 23
view all 10 authors...
Coronavirus disease 2019 (COVID-19) has become a major public health problem worldwide since its outbreak in 2019. Currently, the spread of COVID-19 is far from over, and various complications have roused increasing awareness of the public, calling for novel techniques to aid at diagnosis and treatment. Based on the principle of molecular imaging, positron emission tomography (PET) is expected to offer pathophysiological alternations of COVID-19 in the molecular/cellular perspectives and facilit...
Source
#1Andrea Farolfi (UNIBO: University of Bologna)H-Index: 8
#2Nader Hirmas (University of Duisburg-Essen)H-Index: 2
Last. Wolfgang P. Fendler (University of Duisburg-Essen)H-Index: 30
view all 14 authors...
Background: Prostate-specific membrane antigen (PSMA)-ligand positron-emission-tomography (PSMA-PET) is potentially useful for screening of castration resistant prostate cancer (CRPC) clinical trial target populations. Aim: We investigated the impact of PSMA-PET on Prostate Cancer Clinical Trials Working Group 3 (PCWG3) clinical subtype classification when compared to conventional imaging (CI). Methods: Multicenter retrospective study enrolling patients with (a) PSMA-PET for CRPC, (b) PSA values...
2 CitationsSource
#1Courtney Lawhn-Heath (UCSF: University of California, San Francisco)H-Index: 7
#2Ali Salavati (Johns Hopkins University)
Last. Thomas A. HopeH-Index: 39
view all 10 authors...
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals are playing a large role at the time of initial staging and biochemical recurrence for localizing prostate cancer, as well as in other emerging clinical settings. PSMA PET has demonstrated increased detection rate compared with conventional imaging and has been shown to change management plans in a substantial percentage of cases. The aims of this narrative review are to highlight the development and clinical impact of PSMA ...
Source
#2Dennie Meijer (Centra)
Last. D.E. Oprea-Lager (Centra)H-Index: 1
view all 11 authors...
Het doel van deze studie was om de rol van PSMA-PET/CT vast te stellen bij patienten met biochemische persistentie (BCP) van prostaatkanker na robotgeassisteerde laparoscopische radicale prostatectomie (RALP). Geincludeerd werden 150 patienten met BCP na RALP, bij wie een PSMA-PET/CT-scan werd gemaakt. Een multivariabele logistische regressieanalyse werd uitgevoerd ter identificatie van voorspellers voor de detectie van metastasen buiten de prostaatloge (≥miN1) op PSMA-PET/CT. Bij 89/150 patient...
Source
#1Reona Sakemura (Mayo Clinic)H-Index: 9
#2Ismail Can (Mayo Clinic)
Last. Saad S. KenderianH-Index: 19
view all 4 authors...
Abstract Chimeric antigen receptor T (CART) cells are a promising immunotherapy that has induced dramatic anti-tumor responses in certain B cell malignancies. However, CART expansion and trafficking are often insufficient to yield long-term remissions, and serious toxicities can arise after CART cell administration. Visualizing CART expansion and trafficking in patients can detect inadequate CART response or serve as an early warning for toxicity development, allowing CART treatment to be tailor...
Source
#1Lars Edenbrandt (University of Gothenburg)H-Index: 35
#2Pablo BorrelliH-Index: 4
view all 5 authors...
PurposeProstate-specific membrane antigen (PSMA) PET/CT has shown to be more sensitive and accurate than conventional imaging. Visual interpretation of the images causes both intra- and inter-reader disagreement and there is therefore a need for objective methods to analyze the images. The aim of this study was to develop an artificial intelligence (AI) tool for PSMA PET/CT and to evaluate the influence of the tool on inter-reader variability. ApproachWe have recently trained AI tools to automat...
Source
#1Niamh M Keegan (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 2
#2Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
Last. Michael J. Morris (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 66
view all 3 authors...
CONTEXT Men with biochemically relapsed prostate cancer face a clinical conundrum. Depending on the detected distribution of disease, treatment goals may range from cure with focal therapy to palliative with systemic therapy to expectant observation. Retrospective studies of prostate-specific membrane antigen (PSMA)-based imaging demonstrate higher disease detection rates than conventional imaging. OBJECTIVE This review focuses on available prospective evidence for diagnostic use of PSMA-based i...
Source
#1Ao LiuH-Index: 4
Last. Danfeng XuH-Index: 10
view all 9 authors...
Purpose This study aimed to evaluate the clinical utility of 18F-PSMA-1007 positron emission tomography (PSMA PET)/magnetic resonance imaging (MRI) imaging in patients with suspected or defined prostate cancer. Methods In the pilot study, we retrospectively investigated 62 patients who underwent PSMA-PET/MRI for suspected or defined PCa between June 2019 and June 2020. Patients were grouped into three subgroups: (1) suspected PCa without histological evidence, (2) primary PCa, (3) biochemical re...
Source
#1Mikhail Kesler (Tel Aviv Sourasky Medical Center)H-Index: 3
#2Ido Druckmann (Tel Aviv Sourasky Medical Center)
Last. Einat Even-Sapir (TAU: Tel Aviv University)H-Index: 44
view all 6 authors...
Bone metastases from prostate cancer (PCa) often show an increase in density on computed tomography (CT) after successful androgen deprivation therapy (ADT). Density may be reduced, however, as the disease progresses or, contrarily, when disease is no longer active. The current study investigated the role of 68Ga-PSMA-11 positron emission tomography/computed tomography (PET/CT) in differentiating between these two conditions. Methods: The study cohort included 15 PCa patients with sclerotic/blas...
Source